Literature DB >> 21908500

BRCA in breast cancer: ESMO Clinical Practice Guidelines.

J Balmaña1, O Díez, I T Rubio, F Cardoso.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21908500     DOI： 10.1093/annonc/mdr373

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  64 in total

1.  Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2.

Authors:  Somayeh Ahmadloo; Hirofumi Nakaoka; Takahide Hayano; Kazuyoshi Hosomichi; Hua You; Emi Utsuno; Takafumi Sangai; Motoi Nishimura; Kazuyuki Matsushita; Akira Hata; Fumio Nomura; Ituro Inoue
Journal:  J Hum Genet       Date:  2017-02-09       Impact factor: 3.172

2.  Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.

Authors:  Axel Muendlein; Bettina H Rohde; Klaus Gasser; Anton Haid; Stephanie Rauch; Elena Kinz; Heinz Drexel; Wera Hofmann; Verena Schindler; Rita Kapoor; Thomas Decker; Alois H Lang
Journal:  J Cancer Res Clin Oncol       Date:  2015-05-15       Impact factor: 4.553

3.  Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.

Authors:  Xinglei Chai; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Peter J Hulick; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joanne L Blum; Susan M Domchek; Jinbo Chen; Timothy R Rebbeck
Journal:  Breast Cancer Res Treat       Date:  2014-10-14       Impact factor: 4.872

4.  Public perspectives on the use of preimplantation genetic diagnosis.

Authors:  William D Winkelman; Stacey A Missmer; Dale Myers; Elizabeth S Ginsburg
Journal:  J Assist Reprod Genet       Date:  2015-03-11       Impact factor: 3.412

Review 5.  Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.

Authors:  Santiago Escrivá-de-Romaní; Miriam Arumí; Esther Zamora; Meritxell Bellet
Journal:  Breast Care (Basel)       Date:  2018-08-14       Impact factor: 2.860

Review 6.  Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.

Authors:  Daniel R Principe; Suneel D Kamath; Hidayatullah G Munshi; Nisha A Mohindra
Journal:  Oncologist       Date:  2019-11-01

7.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Authors:  Priyanka Sharma; Jennifer R Klemp; Bruce F Kimler; Jonathan D Mahnken; Larry J Geier; Qamar J Khan; Manana Elia; Carol S Connor; Marilee K McGinness; Joshua M W Mammen; Jamie L Wagner; Claire Ward; Lori Ranallo; Catherine J Knight; Shane R Stecklein; Roy A Jensen; Carol J Fabian; Andrew K Godwin
Journal:  Breast Cancer Res Treat       Date:  2014-05-07       Impact factor: 4.872

8.  High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.

Authors:  Rachel A Sanford; Juhee Song; Angelica M Gutierrez-Barrera; Jessica Profato; Ashley Woodson; Jennifer Keating Litton; Isabelle Bedrosian; Constance T Albarracin; Vicente Valero; Banu Arun
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

9.  Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.

Authors:  L Moreno; C Linossi; I Esteban; N Gadea; E Carrasco; S Bonache; S Gutiérrez-Enríquez; C Cruz; O Díez; J Balmaña
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

10.  Fanconi anemia: correlating central nervous system malformations and genetic complementation groups.

Authors:  Benjamin A Johnson-Tesch; Rakhee S Gawande; Lei Zhang; Margaret L MacMillan; David R Nascene
Journal:  Pediatr Radiol       Date:  2017-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.